MSD probed by UK for blocking Remicade biosimilars

The Competition and Markets Authority (CMA) issued a ‘statement of objections’ against the pharma company - known as Merck &Co in North America - saying that the discount scheme for Remicade (infliximab) was ... The action is the latest in a series

EU starts investigation of Aspen's cancer drug pricing

Last December, Pfizer was fined £84m by the Competitions and Markets Authority (CMA) for conspiring with Flynn Pharma to raise the price of epilepsy drug phenytoin, and the CMA has since

Pfizer gets record £84m fine for hiking price of epilepsy drug

US firm plans to appeal after CMA finds it raised NHS fee by 2, 600% in 2012. ... The Competition and Markets Authority (CMA) has levied an £84.2m fine on Pfizer - as well as a £5.2m penalty for distributor Flynn Pharma - saying they hiked the price of

UK government fines GSK over 'pay-for-delay' deals

The CMA's decision relates to activities between 2001 and 2004 in which GSK agreed to pay £50m to companies supplying generic versions of Seroxat (paroxetine) in order to delay their ... GSK says it rejects the CMA's interpretation of the events. In a

Pfizer and Flynn accused of overcharging for epilepsy drug

By 2013, the cost to the NHS had rocketed up to £50m, says the CMA in a 'statement of objections' released yesterday. ... Businesses are generally free to set prices as they see fit," said Ann Pope, the CMA's senior director of antitrust enforcement.

Five things you didn't realise you already know about influencer marketing

The Advertising Standards Authority (ASA) and Competitions and Markets Authority (CMA) have been applying stricter guidelines and monitoring the industry more closely. ... Always seek advice from the agency you’re working with or directly from the ASA

Stakeholder dialogue in Europe’s adaptive pathways pilot

The use of real-world evidence (RWE) as a complement to clinical trial data to support reimbursement decisions after Conditional Marketing Authorisation (CMA) is granted.

Healthcare systems

Drug pricing

Drug R&D